The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature

Pettit, Laura; El-Modir, Ahmed

doi:10.1259/bjr/16436465

Cited by 10 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, an objective response to octreotide may be observed later, and two months of octreotide monotherapy may not be sufficient for response [5]. Successful somatostatin analogue therapy has been observed in reported cases of advanced, heavily pretreated, and unresectable thymoma, in which treatment with octreotide and prednisolone resulted in complete remission or tumor size reduction [8,9].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Complete Remission of Recurrent Unresectable Thymoma Type B2 under Somatostatin Analogue Treatment. Case Report

Wieczorek-Rutkowska¹,

Serkies²,

Kowalski³

et al. 2019

Mathews Journal of Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long-Term Complete Remission of Recurrent Unresectable Thymoma Type B2 under Somatostatin Analogue Treatment. Case Report

Wieczorek-Rutkowska¹,

Serkies²,

Kowalski³

et al. 2019

Mathews Journal of Case Reports

View full text Add to dashboard Cite

“…In recent years, OCT has been reported to have antitumor effects (12,(29)(30)(31)(32). Compared with traditional chemotherapeutics, OCT has a better specificity, fewer side-effects and is harder to acquire resistance.…”

Section: Discussionmentioning

confidence: 99%

Treatment of liver cancer in mice by the intratumoral injection of an octreotide-based temperature-sensitive gel

Zhang

Duan

et al. 2013

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Octreotide (OCT) can inhibit tumor growth with few side‑effects. In this study, we hypothesized that an OCT- and poloxamer 407 (P407)-based temperature‑sensitive gel may compensate for the short half‑life of OCT, which may thus lead to the development of a novel therapy for patients with end‑stage liver cancer by intratumoral injection. The proliferation and apoptosis of mouse Hca‑F hepatocellular carcinoma cells were determined by MTT assay and Annexin V‑PI staining. A mouse model of hepatocellular carcinoma was established by the subcutaneous transplantion of Hca‑F cells and OCT‑P407 or OCT solution were injected into the tumors, followed by the detection of OCT levels by high performance liquid chromatography (HPLC) over a specific time period. OCT‑P407, ethanol, OCT, P407 or normal saline (NS) were injected into the tumors and the tumor size, weight and inhibition rate were measured 8 days later. Additionally, the expression of somatostatin receptor‑2 (SSTR‑2), vascular endothelial growth factor (VEGF) and caspase‑3 was detected by immunohistochemistry and RT‑PCR. Compared with the OCT group, the tumor inhibition rate and the apoptotic rate in the OCT‑P407 group were higher and the effects were longer. The tumor size and weight in the OCT‑P407 group were lower and the tumor inhibition rate higher compared with the OCT, P407 and NS groups, with the exception of the ethanol group. The protein and mRNA expression of SSTR‑2 and caspase‑3 in the OCT‑P407 group was higher, and that of VEFG was lower compared with the other groups, with the exception of the ethanol group. In the present study, we demonstrate that the intratumoral injection of OCT‑P407 maintains OCT local effective concentration and prolongs its action time, with a greater therapeutic effect than that of OCT on its own. Although ethanol is more effective in certain aspects, its tumor inhibitory effects are similar to OCT‑P407 and as such, OCT‑P407 may be a suitable alternative.

show abstract

“…A pretreated patient reportedly showed a good clinical and radiological response to third-line palliative octreotide plus steroid therapy with a positive octreotide scan [49].…”

Section: Single-case Reportsmentioning

confidence: 99%

The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Montella

Ottaviano

Morra

et al. 2022

Cancers

View full text Add to dashboard Cite

Thymic epithelial tumors are rare tumors usually presenting as a mass located in the anterior mediastinum and/or with symptoms deriving from associated paraneoplastic syndromes. Unresectable platinum-refractory tumors are often treated with alternative regimens, including chemotherapeutic agents as well as chemo-free regimens. The most popular unconventional therapy is represented by the somatostatin analog octreotide, which can be used alone or with prednisone. The in vivo expression of somatostatin receptors documented by imaging with indium-labeled octreotide or gallium-68 Dotapeptides, the successful use of octreotide and prednisone in a chemo-refractory patient, and, thereafter, the experiences from a case series have enforced the idea that this treatment merits consideration—as proved by its inclusion in the National Comprehensive Cancer Network guidelines. In the present review, we analyze the preclinical basis for the therapeutic use of somatostatin and prednisone in refractory thymic tumors and discuss the available studies looking at future perspectives.

show abstract

The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature

Cited by 10 publications

References 9 publications

Long-Term Complete Remission of Recurrent Unresectable Thymoma Type B2 under Somatostatin Analogue Treatment. Case Report

Long-Term Complete Remission of Recurrent Unresectable Thymoma Type B2 under Somatostatin Analogue Treatment. Case Report

Treatment of liver cancer in mice by the intratumoral injection of an octreotide-based temperature-sensitive gel

The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Contact Info

Product

Resources

About